11-18-2022 | Dapagliflozin | News
People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.
11-08-2022 | SGLT2 inhibitors | News
A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.
10-21-2022 | Cardiovascular disorders | News
The strength of the association between diabetes and the risk for cardiovascular events has lessened over recent years, report researchers.
12-20-2022 | Dapagliflozin | News
12-06-2022 | Empagliflozin | News
12-02-2022 | Nephropathy | News
12-01-2022 | Semaglutide | News
11-21-2022 | Cancer | News
11-07-2022 | Lipid-lowering medications | News
11-04-2022 | Empagliflozin | News | Article
10-24-2022 | Cardiovascular outcomes | News
Get the latest developments in diabetes delivered straight to your inbox